These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 20540435)

  • 1. [Low doses of sulphonyluria as a successful replacement for insulin therapy in a patient with neonatal diabetes due to a mutation of KCNJ11 gene encoding Kir6.2].
    Ille J; Putarek NR; Radica A; Hattersley A; Ellard S; Dumić M
    Lijec Vjesn; 2010; 132(3-4):90-3. PubMed ID: 20540435
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diabetes and hypoglycaemia in young children and mutations in the Kir6.2 subunit of the potassium channel: therapeutic consequences.
    Flechtner I; de Lonlay P; Polak M
    Diabetes Metab; 2006 Dec; 32(6):569-80. PubMed ID: 17296510
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outpatient transition of an infant with permanent neonatal diabetes due to a KCNJ11 activating mutation from subcutaneous insulin to oral glyburide.
    Bremer AA; Ranadive S; Lustig RH
    Pediatr Diabetes; 2008 Jun; 9(3 Pt 1):236-9. PubMed ID: 18221420
    [TBL] [Abstract][Full Text] [Related]  

  • 4. KCNJ11 activating mutations in Italian patients with permanent neonatal diabetes.
    Massa O; Iafusco D; D'Amato E; Gloyn AL; Hattersley AT; Pasquino B; Tonini G; Dammacco F; Zanette G; Meschi F; Porzio O; Bottazzo G; Crinó A; Lorini R; Cerutti F; Vanelli M; Barbetti F;
    Hum Mutat; 2005 Jan; 25(1):22-7. PubMed ID: 15580558
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activating mutations in the gene encoding the ATP-sensitive potassium-channel subunit Kir6.2 and permanent neonatal diabetes.
    Gloyn AL; Pearson ER; Antcliff JF; Proks P; Bruining GJ; Slingerland AS; Howard N; Srinivasan S; Silva JM; Molnes J; Edghill EL; Frayling TM; Temple IK; Mackay D; Shield JP; Sumnik Z; van Rhijn A; Wales JK; Clark P; Gorman S; Aisenberg J; Ellard S; Njølstad PR; Ashcroft FM; Hattersley AT
    N Engl J Med; 2004 Apr; 350(18):1838-49. PubMed ID: 15115830
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Diabetes in infants may be treated with sulfonylurea as a replacement for insulin].
    Lauridsen MH; Boesgaard TW; Pedersen OB; Hansen T; Hertz B
    Ugeskr Laeger; 2009 Jun; 171(23):1923-4. PubMed ID: 19500515
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Medical and developmental impact of transition from subcutaneous insulin to oral glyburide in a 15-yr-old boy with neonatal diabetes mellitus and intermediate DEND syndrome: extending the age of KCNJ11 mutation testing in neonatal DM.
    Mohamadi A; Clark LM; Lipkin PH; Mahone EM; Wodka EL; Plotnick LP
    Pediatr Diabetes; 2010 May; 11(3):203-7. PubMed ID: 19686306
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Successful transfer from insulin to oral sulfonylurea in a 3-year-old girl with a mutation in the KCNJ11 gene.
    Al-Mahdi M; Al Mutair A; Al Balwi M; Hussain K
    Ann Saudi Med; 2010; 30(2):162-4. PubMed ID: 20220270
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glibenclamide treatment in permanent neonatal diabetes mellitus due to an activating mutation in Kir6.2.
    Zung A; Glaser B; Nimri R; Zadik Z
    J Clin Endocrinol Metab; 2004 Nov; 89(11):5504-7. PubMed ID: 15531505
    [TBL] [Abstract][Full Text] [Related]  

  • 10. KCNJ11 activating mutations cause both transient and permanent neonatal diabetes mellitus in Cypriot patients.
    Ioannou YS; Ellard S; Hattersley A; Skordis N
    Pediatr Diabetes; 2011 Mar; 12(2):133-7. PubMed ID: 21352428
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Functional effects of mutations at F35 in the NH2-terminus of Kir6.2 (KCNJ11), causing neonatal diabetes, and response to sulfonylurea therapy.
    Proks P; Girard C; Baevre H; Njølstad PR; Ashcroft FM
    Diabetes; 2006 Jun; 55(6):1731-7. PubMed ID: 16731836
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel mutation causing DEND syndrome: a treatable channelopathy of pancreas and brain.
    Shimomura K; Hörster F; de Wet H; Flanagan SE; Ellard S; Hattersley AT; Wolf NI; Ashcroft F; Ebinger F
    Neurology; 2007 Sep; 69(13):1342-9. PubMed ID: 17652641
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Variable phenotypic spectrum of diabetes mellitus in a family carrying a novel KCNJ11 gene mutation.
    D'Amato E; Tammaro P; Craig TJ; Tosi A; Giorgetti R; Lorini R; Ashcroft FM
    Diabet Med; 2008 Jun; 25(6):651-6. PubMed ID: 18544102
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neonatal diabetes mellitus: description of two Puerto Rican children with KCNJ11 activating gene mutation.
    Nieves-Rivera F; González-Pijem L
    P R Health Sci J; 2011 Jun; 30(2):87-9. PubMed ID: 21682153
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Successful sulfonylurea treatment of a neonate with neonatal diabetes mellitus due to a new KCNJ11 mutation.
    Ješić MM; Ješić MD; Maglajlić S; Sajić S; Necić S
    Diabetes Res Clin Pract; 2011 Jan; 91(1):e1-3. PubMed ID: 21056492
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sulfonylurea improves CNS function in a case of intermediate DEND syndrome caused by a mutation in KCNJ11.
    Mlynarski W; Tarasov AI; Gach A; Girard CA; Pietrzak I; Zubcevic L; Kusmierek J; Klupa T; Malecki MT; Ashcroft FM
    Nat Clin Pract Neurol; 2007 Nov; 3(11):640-5. PubMed ID: 17982434
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Glycemic index of meals and postprandial glycemia in patients with permanent neonatal diabetes due to Kir6.2 gene mutations].
    Klupa T; Małecki M; Skupień J; Szalecki M; Jałowiec I; Surdej B; Myśliwiec M; Sieradzki J
    Przegl Lek; 2007; 64(6):398-400. PubMed ID: 18159846
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutations at the same residue (R50) of Kir6.2 (KCNJ11) that cause neonatal diabetes produce different functional effects.
    Shimomura K; Girard CA; Proks P; Nazim J; Lippiat JD; Cerutti F; Lorini R; Ellard S; Hattersley AT; Barbetti F; Ashcroft FM
    Diabetes; 2006 Jun; 55(6):1705-12. PubMed ID: 16731833
    [TBL] [Abstract][Full Text] [Related]  

  • 19. KCNJ11 activating mutations are associated with developmental delay, epilepsy and neonatal diabetes syndrome and other neurological features.
    Gloyn AL; Diatloff-Zito C; Edghill EL; Bellanné-Chantelot C; Nivot S; Coutant R; Ellard S; Hattersley AT; Robert JJ
    Eur J Hum Genet; 2006 Jul; 14(7):824-30. PubMed ID: 16670688
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Permanent neonatal diabetes by a new mutation in KCNJ11: unsuccessful switch to sulfonylurea.
    Lau E; Correia C; Freitas P; Nogueira C; Costa M; Saavedra A; Costa C; Carvalho D; Fontoura M
    Arch Endocrinol Metab; 2015 Dec; 59(6):559-61. PubMed ID: 26331221
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.